Background The long-term trajectories of estimated glomerular filtration rate (eGFR) and their relation to early proteinuria ...

Pennsylvania Western failed to make the case, a judge ruled, that the requirement infringed on its right to set its own service standards and direct its work force.

Such a puzzle since the patient had neither CVD risk factors nor atherosclerotic changes ...

Apecotrep (BI 764198) is a potential first-in-class, oral, selective TRPC6 inhibitor being investigated as a novel, targeted, non-immunosuppressive therapy in people with primary focal segmental ...

Takeda Pharmaceutical Company Limited ( TAK) Q3 2026 Earnings Call January 29, 2026 5:30 AM EST ...

ManpowerGroup Inc. (NYSE:MAN) Q4 2025 Earnings Call Transcript January 29, 2026 ManpowerGroup Inc. beats earnings ...

Lockheed Martin Corporation ( LMT) Q4 2025 Earnings Call January 29, 2026 8:30 AM EST Good day, and welcome, everyone, to the Lockheed Martin Fourth Quarter and Full Year 2025 Earnings Results ...

For the year ended December 31, 2025, net income was $23.58 million, or $7.66 per diluted share, compared to $34.15 million, ...

Return on Average Assets -- Improved by 28 basis points to 1.16% from 0.88% in Q3 2024. Earnings Per Share -- Rose to $0.47, ...

TAL Education Group (NYSE:TAL) Q3 2026 Earnings Call Transcript January 29, 2026 Operator: Ladies and gentlemen, good day and thank you for standing by. Welcome to the TAL Education Group’s fiscal ...

Not intended for the UK Apecotrep (BI 764198) is a potential first-in-class, oral, selective TRPC6 inhibitor being investigated as a novel, targeted, non-immunosuppressive therapy in people with prima ...

Had she known the northwestern Quebec city of Val d’Or would be blanketed in snow in early November, Montrealer Anne Renaud would definitely not have worn her UGG boots, “which have absolutely no ...